Abstract
Revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has remained controversial due to lack of immunological data and fear of side effects. We re-vaccinated 61 elderly patients (median age 75 years), who had a history of hospital treatment for pneumonia, with PPV on average 5.3 years after their primary vaccination. Revaccination resulted in significant increases of the geometric mean antibody concentration (GMC) and the geometric mean antibody fold increase (GMFI), although to lower levels than after primary vaccination. 36/61 (59%) of the patients responded with a GMFI of ≥2 to ≥2 of six serotypes. Local reactions to revaccination were common (63%), but mild, and there were no serious adverse events. We conclude that revaccination of elderly with PPV after 5–10 years is safe and induce a significant immune response in a majority of persons.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
